Genetic polymorphisms analysis of CYP2D6 in the Uygur population

被引:12
作者
He, Xue [1 ,2 ]
He, Na [1 ,2 ]
Ren, Lisong [3 ]
Ouyang, Yongri [3 ]
Zhang, Ning [1 ,2 ]
Ma, Yini [3 ]
Yuan, Dongya [1 ,2 ]
Kang, Longli [1 ,2 ]
Jin, Tianbo [1 ,2 ,3 ,4 ]
机构
[1] Xizang Mingzu Univ, Sch Med, Key Lab Basic Life Sci Res Tibet Autonomous Reg, Xianyang 712082, Shaanxi, Peoples R China
[2] Xizang Mingzu Univ, Sch Med, Key Lab Mol Genet Mech & Intervent Res High Altit, Xianyang 712082, Shaanxi, Peoples R China
[3] Natl Engn Res Ctr Miniaturized Detect Syst, Xian 710069, Shaanxi, Peoples R China
[4] NW Univ Xian, Sch Life Sci, Xian 710069, Shaanxi, Peoples R China
来源
BMC GENOMICS | 2016年 / 17卷
基金
中国国家自然科学基金;
关键词
Frequency; Genetic polymorphisms; Phenotypic; CYTOCHROME-P450; 2D6; GENOTYPE; BREAST-CANCER; METABOLISM; VARIANTS; THERAPY;
D O I
10.1186/s12864-016-2719-x
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: This study aimed to investigate genetic polymorphisms of CYP2D6 among healthy Uygur individuals. Genetic polymorphisms of CYP2D6 could greatly affect CYP2D6 activity and lead to differences among individuals in drug efficacy or side effects. To investigate genetic polymorphisms of CYP2D6 in the Uygur population, we directly sequenced the whole gene in 96 unrelated, healthy Uygur volunteers from the Xinjiang Uygur Autonomous Region and screened for genetic variants in the promoter, intron, exons, and 3'UTR. Results: We detected 62 genetic polymorphisms of CYP2D6, 16 of which were novel SNP with three novel non-synonymous mutations detected for the first time. The allelic frequencies of CYP2D6*1, *10, *39, and *48 were 0.542, 0.156, 0.068, 0.229, and 0.073, respectively. The frequency of CYP2D6*1/*10 which decreased CYP2D6 enzyme activity was 31.3 %. Conclusions: Our results provided basic information about CYP2D6 polymorphisms, suggested that the enzymatic activities of CYP2D6 might be different within the Uygur ethnic group, and provide a basis for safer drug administration and better therapeutic treatment of Uygur individuals.
引用
收藏
页数:9
相关论文
共 35 条
  • [1] Baclig MO, 2012, INT J MOL EPIDEMIOL, V3, P115
  • [2] Haploview: analysis and visualization of LD and haplotype maps
    Barrett, JC
    Fry, B
    Maller, J
    Daly, MJ
    [J]. BIOINFORMATICS, 2005, 21 (02) : 263 - 265
  • [3] CYP2D6 genotyping by liquid chromatography-electrospray ionization mass spectrometry
    Beer, Beate
    Erb, Robert
    Pitterl, Florian
    Niederstaetter, Harald
    Maronas, Olalla
    Gesteira, Alejandro
    Carracedo, Angel
    Piatkov, Irina
    Oberacher, Herbert
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2011, 400 (08) : 2361 - 2370
  • [4] Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups
    Britzi, M
    Bialer, M
    Arcavi, L
    Shachbari, A
    Kapitulnik, J
    Soback, S
    [J]. THERAPEUTIC DRUG MONITORING, 2000, 22 (05) : 510 - 516
  • [5] Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
    Crews, K. R.
    Gaedigk, A.
    Dunnenberger, H. M.
    Leeder, J. S.
    Klein, T. E.
    Caudle, K. E.
    Haidar, C. E.
    Shen, D. D.
    Callaghan, J. T.
    Sadhasivam, S.
    Prows, C. A.
    Kharasch, E. D.
    Skaar, T. C.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (04) : 376 - 382
  • [6] Falzoi M., 2013, ISRN GENET, V2013, P1
  • [7] Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population
    Friedrich, Deise C.
    Genro, Julia P.
    Sortica, Vinicius A.
    Suarez-Kurtz, Guilherme
    de Moraes, Maria Elizabete
    Pena, Sergio D. J.
    Ribeiro dos Santos, Andrea K.
    Romano-Silva, Marco A.
    Hutz, Mara H.
    [J]. PLOS ONE, 2014, 9 (10):
  • [8] Gor PP, 2010, BREAST CANC, V6, P8
  • [9] Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
    Ingelman-Sundberg, Magnus
    Sim, Sarah C.
    Gomez, Alvin
    Rodriguez-Antona, Cristina
    [J]. PHARMACOLOGY & THERAPEUTICS, 2007, 116 (03) : 496 - 526
  • [10] Ji L, 2002, CHINESE MED J-PEKING, V115, P1780